All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Legend Biotech, Pfizer, Roche, and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insights from real-world experience. The symposium was chaired by Hermann Einsele, with presentations from Marc-Andrea Bärtsch, Gordon Cook, and María-Victoria Mateos, and concluded with a panel discussion focused on practical, real-world considerations for the use, sequencing, and management of toxicities associated with B-cell maturation antigen (BCMA)-directed therapies in multiple myeloma. Explore each session below:
Real-world insights and clinical experience with B-cell maturation antigen (BCMA)-directed therapies for the treatment of multiple myeloma (MM) were presented by Gordon Cook at the recent Multiple Myeloma Hub symposium.
Current applications of B-cell maturation antigen (BCMA)-directed therapies in multiple myeloma (MM) and the evolving clinical landscape were described by Marc-Andrea Bärtsch during the recent Multiple Myeloma Hub symposium.
Key considerations when sequencing novel agents and managing adverse events with BCMA-directed therapies in relapsed/refractory multiple myeloma were discussed by the panel, chaired by Hermann Einsele, during the recent Multiple Myeloma Hub symposium.
Future directions with novel and established B-cell maturation antigen (BCMA)-directed therapies in the multiple myeloma (MM) treatment paradigm were presented by Maria Victoria Mateos at the recent Multiple Myeloma Hub symposium.
This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.
Hermann Einsele
María-Victoria Mateos
Gordon Cook